|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Regulation of MLH1 mRNA and protein expression by promoter methylation in primary colorectal cancer: a descriptive and prognostic cancer marker study显示文摘 | Lars Henrik Jensen Anders Aamann Rasmussen Lene Byriel Hidekazu Kuramochi Dorthe Gylling Crüger Jan Lindebjerg Peter V. Danenberg Anders Jakobsen Kathleen Danenberg | 2013 | Cellular Oncology2013，，5： | 2 |
| 2 | Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus显示文摘 | Reginald V.N. Lord Ji Min Park Kumari Wickramasinghe Steven R. DeMeester Stefan Oberg Dennis Salonga Jon Singer Jeffrey H. Peters Kathleen D. Danenberg Tom R. DeMeester Peter V. Danenberg | 2003 | The Journal of Thoracic and Cardiovascular Surgery2003，，2： | 2 |
| 3 | Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5-FU sensitivity by a histocultural drug sensitivity test显示文摘 | Masaki Kakimoto Hiroyuki Uetake Takayuki Osanai Yoshinori Shirota Yoko Takagi Emiko Takeshita Yoichi Toriya Kathleen Danenberg Peter V. Danenberg Kenichi Sugihara | 2004 | Cancer Letters2004，，1： | 1 |
| 4 | Thymidylate synthase polymorphisms and mRNA expression are independentchemotherapy predictive markers in esophageal adenocarcinoma patients显示文摘 | Hidekazu Kuramochi Koji Tanaka Daniel Oh Bethany Lehman Christy Dunst Dong Yang Steven De Meester Jeffery Hagen Kathleen Danenberg Tom De Meester Peter Danenberg | 2008 | International Journal of Oncology2008，，1： | 1 |
| 5 | Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is corelated with survival显示文摘 | Jan Brabender Kathleen D Danenberg | 2001 | Clinical Cancer Research2001，7，7： | 1 |
| 6 | Response prediction in metastasised colorectal cancer using intratumoural thymidylate synthase: Results of a randomised multicentre trial显示文摘 | Marko Kornmann Holger Hebart Kathleen Danenberg Roland Goeb Ludger Staib Martina Kron Doris Henne-Bruns Peter Danenberg Karl-Heinrich Link | 2011 | European Journal of Cancer2011，，10： | 1 |
| 7 | Telomerase reverse transcriptase expression is increased early in the Barrett’s metaplasia, dysplasia, adenocarcinoma sequence显示文摘 | Reginald V. N. Lord F.R.A.C.S. Dennis Salonga B.S. Kathleen D. Danenberg M.S. Jeffrey H. Peters M.D. Tom R. DeMeester M.D. Ji Min Park B.S. Jan Johansson M.D. Kristin A. Skinner M.D. Para Chandrasoma M.D. Steven R. DeMeester M.D. Cedric G. Bremner M.Ch. P | 2000 | Journal of Gastrointestinal Surgery2000，，2： | 1 |
| 8 | MDR1 and ERCC1 Expression Predict Outcome of Patients with Locally Advanced Bladder Cancer Receiving Adjuvant Chemotherapy显示文摘 | Andreas-Claudius Hoffmann Peter Wild Christina Leicht Simone Bertz Kathleen D. Danenberg Peter V. Danenberg Robert St?hr Michael St?ckle Jan Lehmann Martin Schuler Arndt Hartmann | 2010 | Neoplasia2010，，： | 1 |
| 9 | Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/clsplatin- treated advanced non -small cell lung cancer patients显示文摘 | Rafael Rosell Kathleen D Danenberg Vincente Alberola | 2004 | Clin Cart Res2004，10，： | 1 |
| 10 | High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1显示文摘 | Hidekazu Kuramochi Kazuhiko Hayashi Kazumi Uchida Go Nakajima Takashi Hatori Kathleen D. Danenberg Peter V. Danenberg Masakazu Yamamoto | 2008 | Cancer Chemotherapy and Pharmacology2008，，1： | 1 |
| 11 | Ribonu- cleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin - treated advanced non - small cell lung cancer patients 显示文摘 | Rafael Rosell Kathleen D Danenberg Vincente Mberola | 2004 | Clin Cancer Res2004，10，： | 1 |
| 12 | Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer显示文摘 | David R. Gandara Peter Grimminger Philip C. Mack Primo N. Lara Tianhong Li Peter V. Danenberg Kathleen D. Danenberg | 2010 | Journal of Thoracic Oncology2010，，12： | 1 |
| 13 | Histology-Related Associations of ERCC1, RRM1, and TS Biomarkers in Patients with Non–Small-Cell Lung Cancer: Implications for Therapy显示文摘 | Martin K.H. Maus Philip C. Mack Stephanie H. Astrow Craig L. Stephens Gary D. Zeger Peter P. Grimminger Jack H. Hsiang Eric Huang Tianhong Li Primo N. Lara Kathleen D. Danenberg David R. Gandara | 2013 | Journal of Thoracic Oncology2013，，5： | 1 |
| 14 | Epidermal Growth Factor Receptor and HER2 - neu mRNA Expression in Non-Small Cell Lung Cancer is Correlated with Survival显示文摘 | Jan Brabender Kathleen D Danenberg | 2001 | Clinical Cancer Research2001，7，7： | 1 |
| 15 | Telomerase reverse transcriptase expression is increased early in the Barrett’s metaplasia, dysplasia, adenocarcinoma sequence显示文摘 | Reginald V. N. Lord F.R.A.C.S. Dennis Salonga B.S. Kathleen D. Danenberg M.S. Jeffrey H. Peters M.D. Tom R. DeMeester M.D. Ji Min Park B.S. Jan Johansson M.D. Kristin A. Skinner M.D. Para Chandrasoma M.D. Steven R. DeMeester M.D. Cedric G. Bremner M.Ch. P | 2000 | Journal of Gastrointestinal Surgery2000，，2： | 1 |
| 16 | Patient-centered developments in colon-and rectal cancer with a multidisciplinary international team:From translational research to national guidelines显示文摘Rarely,scientific developments centered around the patient as a whole arepublished.Our multidisciplinary group,headed by gastrointestinal surgeons,applied this research philosophy considering the most important aspects of thediseases“colon-and rectal cancer”in the long-term developments.Good expertcooperation/knowledge at the Comprehensive Cancer Center Ulm(CCCU)wereapplied in several phase III trials for multimodal treatments of primary tumors(MMT)and metastatic diseases(involving nearly 2000 patients and 64 centers),fortreatment individualization of MMT and of metastatic disease,for psychooncology/quality of life involving the patients’wishes,and for disease prevention.Most of the targets initially were heavily rejected/discussed in thescientific communities,but now have become standards in treatments andnational guidelines or are topics in modern translational research protocolsinvolving molecular biology for e.g.,“patient centered individualized treatment”.In this context we also describe the paths we had to tread in order to realize ournew goals,which at the end were highly beneficial for the patients from manypoints of view.This description is also important for students and youngresearchers who,with an actual view on our recent developments,might want toknow how medical progress was achieved. | Karl-Heinrich Link Marko Kornmann Ludger Staib Ernst-Dietrich Kreuser Wilhelm Gaus Erwin Röttinger Peter Suhr Catharina Maulbecker-Armstrong Peter Danenberg Kathleen Danenberg Miriam Schatz Silvia Sander Zhen-Ling Ji Jiang-Tao Li Shu-You Peng Reinhard Bittner Hans Günther Beger Benno Traub | 2021 | World Journal of Gastrointestinal Surgery2021，13，12： | 0 |
| 17 | Using cfRNA as a tool to evaluate clinical treatment outcomes in patients with metastatic lung cancers and other tumors显示文摘Aim:We report an exploratory analysis of cfRNA as a biomarker to monitor clinical responses in non-small cell lung cancer(NSCLC),breast cancer,and colorectal cancer(CRC).An analysis of cfRNA as a method for measuring PD-L1 expression with comparison to clinical responses was also performed in the NSCLC cohort.Methods:Blood samples were collected from 127 patients with metastatic disease that were undergoing therapy,52 with NSCLC,50 with breast cancer,and 25 with CRC.cfRNA was purified from fractionated plasma,and following reverse transcription(RT),total cfRNA and gene expression of PD-L1were analyzed by real-time polymerase chain reaction(qPCR)using beta-actin expression as a surrogate for relative amounts of cfDNA and cfRNA.For the concordance study of liquid biopsies and tissue biopsies,the isolated RNA was analyzed by RNAseq for the expressions of 13 genes.We had to close the study early due to a lack of follow-up during the Covid-19 pandemic.Results:We collected a total of 373 blood samples.Mean cfRNA PCR signals after RT were about 50-fold higher than those of cfDNA.cfRNA was detected in all patients,while cfDNA was detected in 88%of them.A high concordance was found for the expression levels of 13 genes between blood and solid tumor tissue.Changes in cfRNA levels followed over the course of treatments were associated with response to therapy,increasing in progressive disease(PD)and falling when a partial response(PR)occurred.The expression of PD-L1 over time in patients treated with immunotherapy decreased with PR but increased with PD.Pre-treatment levels of PD-L1 were predictive of response in patients treated with immunotherapy.Conclusion:Changes in cfRNA correlate with clinical response to the therapy.Total cfRNA may be useful in predicting clinical outcomes.PD-L1 gene expression may provide a biomarker to predict response to PD-L1 inhibition. | Luis E.Raez Kathleen Danenberg Daniel Sumarriva Joshua Usher Jacob Sands Aurelio Castrellon Pablo Ferraro Adriana Milillo Eric Huang Patrick Soon-Shiong Sandeep Reddy Peter Danenberg | 2021 | Cancer Drug Resistance2021，4，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员